PhD in Preclinical Development

Studentship covers home fees and UKRI rate stipend (£21,805 for 26/27)./nThis PhD will develop cellular models and primary cultures from KRASmutant nonsmall cell lung cancer (NSCLC) samples to investigate the efficacy of anticancer therapeutics./nYou will establish and assess NSCLC model systems, including cell lines and patientderived organoids (PDOs); evaluate drug efficacy; study cellular signalling responses; and apply genome editing tools such as CRISPR to explore the underpinning mechanisms./nWorking with patient samples pre and postKRAS inhibitor treatment, you will validate clinically relevant resistance mechanisms./nLocation: Newcastle upon Tyne/nNumber Of Awards: 1/nStart Date: October 2026/nAward Duration: 4 years/nApplication Closing Date: 6th March 2026